RNA Therapies
BIO
Bolstering our biologics services
Recipharm completed a series of strategic acquisitions in April 2022 to bolster its biologics offering, welcoming premier industry CDMO specialists Arranta Bio, GenIbet and Vibalogics to the Recipharm family, integrating the biomanufacturing solutions offering under one business unit, ReciBioPharm. Here, you will have access to the combined expertise of Arranta Bio, GenIbet, Vibalogics and Recipharm, which makes us the CDMO of choice for your project.
The name “ReciBioPharm” places “Bio” at the centre of our biomanufacturing solutions brand. This reflects the importance of our biologics offering to support the needs of customers and patients who receive these critical medicines.
Our expanded biologics drug development and manufacturing services and technologies encompassing the production of mRNA, lipid nanoparticles, plasmid DNA, viral vectors and live virus, and microbiome live biotherapeutics:
- RNA manufacturing
- Lipid nanoparticles
- Plasmid manufacturing
- Cell and viral banking
- Viral vector and live virus
- Microbiome live biotherapeutics
- ATMP fill and finish
Our highest priority is to ensure the production of future medicines with the utmost quality, efficiency and reliability to support your biologics projects.
Want to know more about our full biologics service offering?